<DOC>
	<DOCNO>NCT02477020</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability TAK-063 compare placebo treatment acutely exacerbate schizophrenia .</brief_summary>
	<brief_title>A Phase 2 Efficacy Safety Study TAK-063 Participants With Acute Exacerbation Schizophrenia</brief_title>
	<detailed_description>The drug test study call TAK-063 . TAK-063 test treat people schizophrenia . This study look different symptom associate schizophrenia include cognitive symptom , personal social function functional capacity people take TAK-063 . The study enroll approximately 160 patient . Participants randomly assign ( chance , like flip coin ) one two treatment groupsâ€”which remain undisclosed patient study doctor study ( unless urgent medical need ) : - TAK-063 20 mg - Placebo ( dummy inactive pill ) - tablet look like study drug active ingredient . All participant ask take tablet daily nighttime . All participant initially receive TAK-063 , 20 mg/day . The dose may titrate 10 mg/day , intolerable . The multi-center trial conduct United States . The overall time participate study 6 week . Participants hospitalize Week 3 visit . Participants make 11 visit clinic treatment 1 visit follow-up .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1 . Is capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Has primary diagnosis schizophrenia ( Diagnostic Statistical Manual Mental Disorders , 5th Edition [ DSM5 ] , 295.90 ) confirm clinical interview ( Structured Clinical Interview DSM5 Clinical Trial Version [ SCID5CT ] ) .The participant 's initial diagnosis must great equal ( &gt; = ) 1 year screening . 4 . Is man woman age 18 65 , inclusive , Screening . 5 . Male participant nonsterilized sexually active female partner child bear potential agrees use adequate contraception signing inform consent throughout duration study 12 week last dose . 6 . Female participant childbearing potential sexually active nonsterilized male partner agree use adequate contraception signing inform consent throughout duration study 12 week last dose . 7 . The participant 's psychotic symptom exacerbate within 2 month ( 60 day ) prior Screening ( example , aggravate delusion ) . 8 . Has score 5 ( moderate severe ) high 3 item follow PANSS item Screening Day 1 : delusion ( P1 ) , conceptual disorganization ( P2 ) , hallucination ( P3 ) , suspiciousness ( P6 ) , unusual thought content ( G9 ) . 9 . Has PANSS total score 80 high Screening Day 1 . 10 . Has CGIS 4 great Screening Day 1 . 11 . Is able agrees remain prior antipsychotic medication exclude medication outline protocol duration study . 12 . Has identify , reliable caregiver . A caregiver define family member , informant friend able willing assist support administration study drug , adherence protocol requirement study schedule . 13 . Has body mass index ( BMI ) score 18.0 35.0 kilogram per square meter ( kg/m^2 ) , inclusive , Screening . 1 . Has receive investigational compound within 30 day prior Screening , within 5 halflives prior screen , whichever longer . 2 . Has receive TAK063 previous clinical study therapeutic agent previously currently participate study participate 2 clinical study within 12 month prior Screening . 3 . Has decrease PANSS Total Score 20 percent ( % ) Baseline ( Day 1 ) compare Screening [ ( PANSS Total Score Screening PANSS total score Baseline ) / ( PANSS Total Score Screening 30 ) ] *100 &gt; =20 % ] . 4 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( example , spouse , parent , child , sibling ) may consent duress . 5 . Has uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , endocrine disease abnormality ( disease study ) , may impact ability subject participate potentially confound study result . 6 . Has history severe head injury/traumatic brain injury , myocardial infarction stroke . 7 . Has know hypersensitivity component formulation TAK063 practice pill ( i.e. , small colored candy ) AiCure device training . 8 . Has positive urine drug result ( illicit , illegal without valid prescription medical need ) Screening . 9 . Has moderate severe substance use disorder ( meet 5 diagnostic criterion DSM5 either currently within last 6 month ) alcohol substance abuse except nicotine caffeine . 10 . Has take exclude medication , supplement , food product insufficient washout medication , supplement , food product list Excluded /Allowed Medications , Procedures , Treatments table unable unwilling discontinue medication require protocol . 11 . If female , participant pregnant lactate intend become pregnant ( positive pregnancy test Screening Day 1 ) , intend donate ovum , course study within 12 week last dose . 12 . If male , participant intend donate sperm course study 12 week last dose . 13 . Has psychiatric disorder schizophrenia primary diagnosis . 14 . Has history know personality disorder psychiatric disorder , opinion investigator , would interfere participation study . 15 . Has history neuroleptic malignant syndrome , water intoxication , paralytic ileus condition may interfere absorption study medication . 16 . Is consider investigator imminent risk suicide injury self , others , property subject within past year prior Screening attempt suicide positive answer item 4 5 Columbia Suicide Severity Rating Scale ( CSSRS ) Screening Day 1 . 17 . Has Parkinson disease , tardive dyskinesia , chronic movement disorder may interfere interpretation study result . 18 . Has exist previous history cancer remission le 5 year prior Screening . ( This criterion include subject basal cell , stage I squamous cell skin cancer situ cervical cancer ) . 19 . Has newly diagnose diabetes require insulin treatment icsubjects change diabetic treatment regimen within 30 day prior screen diabetic subject hospitalization diabetes and/or diabetes related condition past year prior screen . 20 . Has long QT syndrome treatment Class 1A ( example , quinidine , procainamide ) Class 3 ( example , amiodarone , sotalol ) antiarrhythmic drug . 21 . Is know currently infect infect human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) . 22 . Has receive depot preparation ( sustainedrelease formulation ) antipsychotic drug within 1 month ( 30 day ) Screening . 23 . Has receive clozapine treatment schizophrenia ( lifetime ) screening ( include use lowdose clozapine sleep ) . 24 . Has receive monoamine oxidase ( MAO ) inhibitor fluoxetine within 1 month ( 30 day ) Screening . 25 . Is consider treatment resistant . Treatment resistance define prior nonresponse 2 course treatment antipsychotic different chemical class least 4 week dose consider effective . 26 . Has receive electroconvulsive therapy within 6 month ( 180 day ) Screening . 27 . Has history hypersensitivity one distinct chemical class drug ( include anaphylaxis , rash , urticaria cause drug ) . 28 . Is consider otherwise inappropriate study investigator Sponsor 's medical monitor and/or designee . 29 . Has 1 laboratory value outside normal range consider investigator clinically significant Screening Visit ; follow Screening Visit : serum creatinine value &gt; 1.5 time upper limit normal ( ULN ) . A total serum total bilirubin value &gt; 1.5*ULN . A serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value &gt; 2*ULN , prolactin &gt; = 100 nanogram/milliliter ( ng/mL ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>